Pure Global

Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT) - UK MHRA Medical Device Registration

Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT) is a medical device registered with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) under Device ID 153043. The device is manufactured by Exosome Diagnostics Inc. from United States, classified as In Vitro Diagnostic Device. The authorized representative in the UK is Emergo Consulting (UK) Limited .

This page provides comprehensive regulatory information including complete registration details, manufacturer information, device classification, authorized representative details, and related products. Pure Global AI offers free access to 150,962+ UK MHRA medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
MHRA Registered
In Vitro Diagnostic Device
๐Ÿ‡ฌ๐Ÿ‡ง
Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT)
MHRA Device ID: 153043โ€ขRef: 153043

Device Type

In Vitro Diagnostic Device

Devices

Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT)

Type

IVD General

Date Registered

Jul 28, 2022

Last Updated

Dec 22, 2022

Manufacturer Information

Address

266 Second Ave. Suite 200

Waltham, Massachusetts, United States

Created Date

Jul 28, 2022

Authorized Representative

Relationship Type

UK Responsible Person

Address

Compass House, Vision Park Histon c/o Cr360 โ€“ UL International

Cambridge, England, United Kingdom

Postcode: CB24 9BZ

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing